Merck Completes Mirus Bio Acquisition, Enhancing Viral Vector Bioprocessing Portfolio
Merck, a leading science and technology company, has announced the completion of its acquisition of Mirus Bio for approximately US$ 600 million (€ 550 million), following regulatory clearances and the fulfillment of other customary closing conditions. This acquisition is a…